Cart
0

Asthma and COPD Drugs Market by Disease (COPD and Asthma) by Medication Class (Combination Drugs, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics and Others) - Global Opportunity Analysis and Industry Forecasts, 2014-2022

Get 20% Free Customization In This Report
LI_16311
Pages: 120
Oct 2016 | 4861 Views
 
Author's : Sachin Sinha
Tables: 65
Charts: 65
 

Asthma and COPD Drugs Market Overview:

The Global Asthma and COPD Drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Asthma is a chronic respiratory disease blocking the airways of lung because of inflammation, mucus production, tighten of muscles. Chronic Obstructive Pulmonary Disease(COPD) is caused by obstruction in the airways causing difficulty in breathing, with the primary cause as tobacco smoking.

Symptoms of Asthma and COPD

Symptoms of Asthma and COPD

Get more information on this report : Request Sample Pages

This report covers information on various types of medication class to treat asthma and COPD in compliance with the European Medical Association (EMA), the U.S. Food and Drugs Administration (FDA), Conformité Européene (CE) and other regulatory authorities. Moreover, this study on the global Asthma and COPD Drugs also focuses on the treatment of the disease which is available in the market.

The Global Asthma and COPD Drugs market is segmented based on disease, medication class and geography. Based on disease, the market is categorized into asthma and COPD. Based on medication class, the market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Based on geography, the market is categorized into North America, Europe, Asia-Pacific, and LAMEA. North America holding major share of the market.

Asthma and COPD Drugs Market Segmentation

Asthma and COPD Drug Market Key Segments

Get more information on this report : Request Sample Pages

The use of drugs has emerged as an effective solution for the treatment of COPD and asthma, which largely contributes to the growth of this market. The market is driven by the growing patient COPD and asthmatic population, as well as FDA approvals for the novel products and its wide acceptance among the patient population. Increasing government initiatives to control COPD and asthma further fuel the growth for this market.

The Asthma and COPD Drug market consists of medication class based on the severity of the disease. Short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids(ICS), leukotriene antagonists (LTA), combination products, anticholinergics and others are the medication class which are used in the treatment of COPD and asthma.

The disease segment consists of the global prevalence of asthma and COPD for market sizing and forecasting the global sales of the Asthma and COPD Drugs. Asthma contributed the highest share, approximately 66.1%, to the world Asthma and COPD Drugs market with the expected to grow at a highest CAGR of 1.3% by 2022.

The growth of the North American and European market is driven by the increasing COPD and asthma patient population and rising number of smokers. North American Asthma and COPD Drugs market is likely to register a CAGR of 3.2% over the analysis period, which would create potential opportunities for new market players to grow.

Top impacting factors

Increase in prevalence of COPD and asthma patients; increase in world ageing population, technological advancement in the treatment of asthma and COPD, increase in pipeline products growth in initiatives implemented by the government and non-government associations for rise in health awareness are the major factors that drive the growth of the Asthma and COPD Drug.

However, stringent government regulatory requirement for the approval of asthma and COPD drugs, the asthma and COPD drugs showing side effects, patent expiry of the drugs restrict the market growth. Furthermore, developing countries, such as China and India, provide huge growth opportunities along with introduction of generic drugs to this market.

The leading market players in the Asthma and COPD Drug focus to expand their business operations in the emerging countries. The companies operating in the market have consistently introduced innovative solutions to enhance their product portfolio. Product approval and clinical trial are observed as the two prominent growth strategies adopted by the key market players. The major players profiled in this report include GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. (U.S), Abbott Laboratories (U.S), Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries (Israel), Vectura Group (U.K), Pfizer (U.S).

Other players in the value chain include Mylan, Aerovance Inc. Alkermes Inc. Almirall SA. Genentech Inc. Sepracor, Inc. Skyepharma plc.

Asthma and COPD Drugs Market

Get more information on this report : Request Sample Pages

Asthma and COPD Drugs Market Key benefits

  • The study provides an in-depth analysis of the asthma and COPD drug market with current trends and future estimations to elucidate the imminent investment pockets in the market.
  • The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the asthma and COPD drug market, by medication class, helps in the treatment of asthma and COPD diseases.
  • Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
  • Key market players within the asthma and COPD drug market are profiled in this report and their strategies are analyzed thoroughly, which predicts the competitive outlook of global asthma and COPD drug market.

ASTHMA AND COPD DRUGS MARKET KEY SEGMENTS

By Diseases

  • COPD
  • Asthma

By Medication Class

  • Combination Products
    • Seretide/Advair
    • Symbicort
    • Relvar/Breo Ellipta
    • Flutiform
    • Dulera
    • Others
  • Leukotriene Antagonists (LTA)
    • Singulair
    • Others
  • Inhaled Corticosteroids (ICS)
    • Qvar
    • Pulmicort
    • Aerospan
    • Flovent
    • Others
  • Anticholinergics
    • Spiriva
    • Others
  • Short Acting Beta Agonists(SABA)
    • ProAir
    • Ventolin
    • Others
  • Long Acting Beta Agonists (LABA)
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • France
    • Germany
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa
 

Chapter: 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO perspective

Chapter: MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top investment pockets
3.2.2 Top winning strategies

3.3 Porters five forces analysis

3.3.1 Bargaining power of buyers (High)
3.3.2 Bargaining power of suppliers (Low to Moderate)
3.3.3 Threat of new entrants (Low)
3.3.4 Threat of substitutes (High)
3.3.5 Intense competitive rivalry

3.4 Market dynamics

3.4.1 Drivers

3.4.1.1 Increasi in number of asthmatic and COPD patients worldwide
3.4.1.2 Increase in world ageing population
3.4.1.3 Technological advancement in the treatment of asthma and COPD drugs
3.4.1.4 Initiatives taken by various government associations to raise awareness about daignosis and management of asthma and COPD
3.4.1.5 Increasing number of products in the pipeline

3.4.2 Restraints

3.4.2.1 Stringent regulatory requirements for the approval and commercialization of asthma and COPD drugs
3.4.2.2 Asthma and COPD drugs show side effects
3.4.2.3 Asthma and COPD drug approval process is expensive and time-consuming
3.4.2.4 Patent expiry of asthma and COPD drugs

3.4.3 Opportunities

3.4.3.1 Inrtoduction of generic drugs of asthma and COPD drugs

3.5 Market share analysis, 2015

Chapter: 4 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASE

4.1 Overview
4.2 Asthma

4.2.1 Global prevalence
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 COPD

4.3.1 Global prevalence
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

Chapter: 5 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS

5.1 Overview
5.2 Combination Drugs

5.2.1 Market size and forecast
5.2.2 Seretide/Advair
5.2.3 Symbicort
5.2.4 Relvar/Breo Ellipta
5.2.5 Flutiform
5.2.6 Dulera

5.3 Leukotriene antagonists (LTA)

5.3.1 Market size and forecast
5.3.2 Singulair

5.4 Inhaled corticosteroids (ICS)

5.4.1 Market size and forecast
5.4.2 Qvar
5.4.3 Pulmicort
5.4.4 Aerospan
5.4.5 Flovent

5.5 Anticholinergics

5.5.1 Market size and forecast
5.5.2 Spiriva

5.6 Short acting beta agonists (SABA)

5.6.1 Market size and forecast
5.6.2 ProAir
5.6.3 Ventolin

5.7 Long acting beta agonists (LABA)

5.7.1 Market size and forecast

5.8 Others

5.8.1 Market size and forecast

Chapter: 6 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022

6.1 Overview

6.1.1 Market size and forecast

6.2 North America

6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 U.S.: market size and forecast
6.2.5 Canada market size and forecast
6.2.6 Mexico: market size and forecast

6.3 Europe

6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Germany: market size and forecast
6.3.4 France market size and forecast
6.3.5 UK: market size and forecast
6.3.6 Italy market size and forecast
6.3.7 Rest of Europe: market size and forecast

6.4 Asia-Pacific

6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Japan: market size and forecast
6.4.5 China market size and forecast
6.4.6 India: market size and forecast
6.4.7 Rest of Asia-Pacific market size and forecast

6.5 LAMEA

6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.5.4 Latin America: market size and forecast
6.5.5 Middle East market size and forecast
6.5.6 Africa: market size and forecast

Chapter: 7 GLOBAL ASTHMA AND COPD DRUGS PIPELINE -2015

Chapter: 8 COMPANY PROFILES

8.1 Boehringer Ingelheim International GmbH

8.1.1 Company overview
8.1.2 Operating business segments
8.1.3 Business performance
8.1.4 Key strategic moves & developments

8.2 Merck & Co., Inc.

8.2.1 Company overview
8.2.2 Operating business segments
8.2.3 Business performance
8.2.4 Key strategic moves & developments

8.3 GlaxoSmithKline PLC.

8.3.1 Company overview
8.3.2 Operating business segments
8.3.3 Business performance
8.3.4 Key strategic moves & developments

8.4 Novartis AG

8.4.1 Company overview
8.4.2 Operating business segments
8.4.3 Business performance
8.4.4 Key strategic moves & developments

8.5 AstraZeneca

8.5.1 Company overview
8.5.2 Operating business segments
8.5.3 Business performance
8.5.4 Key strategic moves & developments

8.6 F. Hoffmann-La Roche Ltd

8.6.1 Company overview
8.6.2 Operating business segments
8.6.3 Business performance
8.6.4 Key strategic moves & developments

8.7 Teva Pharmaceutical Industries Ltd.

8.7.1 Company overview
8.7.2 Operating business segments
8.7.3 Business performance
8.7.4 Key strategic moves & developments

8.8 Vectura Group plc.

8.8.1 Company overview
8.8.2 Operating business segments
8.8.3 Business performance
8.8.4 Key strategic moves & developments

8.9 Pfizer, Inc.

8.9.1 Company overview
8.9.2 Operating business segments
8.9.3 Business performance
8.9.4 Key strategic moves & developments

8.10 Abbott Laboratories

8.10.1 Company overview
8.10.2 Operating business segments
8.10.3 Business performance
8.10.4 Key strategic moves & developments

List of Figures

FIG. 1 TOP INVESTMENT POCKETS IN GLOBALASTHMA AND COPD DRUGS MARKET
FIG. 2 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2014-2016
FIG. 3 PORTERS FIVE FORCES ANALYSIS OF GLOBAL
ASTHMA AND COPD DRUGS MARKET
FIG. 4 TOP IMPACTING FACTORS: GLOBAL
ASTHMA AND COPD DRUGS MARKET
FIG. 5 GLOBAL
ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2015 & 2022 (% SHARE)
FIG. 6 GLOBAL
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 7 GLOBAL
ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 8 COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 9 COPD DRUGS MARKET, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 10 SERETIDE/ADVAIT MARKET, 2014-2022 ($MILLION)
FIG. 11 SYMBICORT MARKET, 2014-2022 ($MILLION)
FIG. 12 RELVAR/BREO ELLIPTA MARKET, 2014-2022 ($MILLION)
FIG. 13 FLUTIFORM MARKET, 2014-2022 ($MILLION)
FIG. 14 FLUTIFORM MARKET, 2014-2022 ($MILLION)
FIG. 15 SINGULAIR MARKET, 2014-2022 ($MILLION)
FIG. 16 QVAR MARKET, 2014-2022 ($MILLION)
FIG. 17 PULMICORT MARKET, 2014-2022 ($MILLION)
FIG. 18 AEROSPAN MARKET, 2014-2022 ($MILLION)
FIG. 19 FLOVENT MARKET, 2014-2022 ($MILLION)
FIG. 20 SPIRIVA MARKET, 2014-2022 ($MILLION)
FIG. 21 PROAIR MARKET, 2014-2022 ($MILLION)
FIG. 22 PROAIR MARKET, 2014-2022 ($MILLION)
FIG. 23 U.S.:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 24 CANADA:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 25 MEXICO:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 26 GERMANY:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 27 FRANCE:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 28 UK:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 29 ITALY:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 30 REST OF EUROPE:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 31 JAPAN:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 32 CHINA:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 33 INDIA:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 34 REST OF ASIA-PACIFIC:
ASTHMA AND COPD DRUGS DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 35 LATIN AMERICA:
ASTHMA AND COPD DRUGSMARKET, 2014-2022 ($MILLION)
FIG. 36 MIDDLE EAST:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 37 AFRICA:
ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 38 BOEHRINGER INGELHEIM: REVENUE, 2013-2015 ($MILLION)
FIG. 39 BOEHRINGER INGELHEIM: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 40 BOEHRINGER INGELHEIM: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 41 MERCK: REVENUE, 2013-2015 ($MILLION)
FIG. 42 MERCK: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 43 MERCK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 44 GSK: REVENUE, 2013-2015 ($MILLION)
FIG. 45 GSK: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 46 GSK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 47 NOVARTIS: REVENUE, 2013-2015 ($MILLION)
FIG. 48 NOVARTIS: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 49 NOVARTIS: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 50 ASTRAZENECA: REVENUE, 2013-2015 ($MILLION)
FIG. 51 ASTRAZENECA: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 52 ASTRAZENECA: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 53 ROCHE: REVENUE, 2013-2015 ($MILLION)
FIG. 54 ROCHE: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 55 ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 56 TEVA: REVENUE, 2013-2015 ($MILLION)
FIG. 57 TEVA: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 58 TEVA: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 59 VECTURA: REVENUE, 2013-2015 ($MILLION)
FIG. 60 PFIZER: REVENUE, 2013-2015 ($MILLION)
FIG. 61 PFIZER: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 62 PFIZER: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 63 ABBOTT: REVENUE, 2013-2015 ($MILLION)
FIG. 64 ABBOTT: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 65 ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)

List of Tables

TABLE 1 ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 2
ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 3 COPD DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 4
ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS TYPE, 2014-2022 ($MILLION)
TABLE 5 COMBINATION DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 6 LTA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 7 ICS DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8 ANTICHOLINERGICS DRUG MARKET, BY GEOGRAPHY,
TABLE 9 2014-2022 ($MILLION)
TABLE 10 SABA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 11 LABA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12 OTHER DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13 GLOBAL
ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 14 NORTH AMERICA:
ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 15 NORTH AMERICA:
ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 16 NORTH AMERICA:
ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 17 EUROPE:
ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 18 EUROPE:
ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 19 EUROPE:
ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 20 ASIA-PACIFIC:
ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 21 ASIA-PACIFIC:
ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 22 ASIA-PACIFIC:
ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 23 LAMEA:
ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 24 LAMEA:
ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 25 LAMEA:
ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 26 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 27 BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 28 MERCK: COMPANY SNAPSHOT
TABLE 29 MERCK: OPERATING SEGMENTS
TABLE 30 GSK: COMPANY SNAPSHOT
TABLE 31 GSK: OPERATING SEGMENTS
TABLE 32 NOVARTIS: COMPANY SNAPSHOT
TABLE 33 NOVARTIS: OPERATING SEGMENTS
TABLE 34 ASTRAZENECA: COMPANY SNAPSHOT
TABLE 35 ASTRAZENECA: OPERATING SEGMENT
TABLE 36 ROCHE: COMPANY SNAPSHOT
TABLE 37 ROCHE: OPERATING SEGMENTS
TABLE 38 TEVA: COMPANY SNAPSHOT
TABLE 39 TEVA: OPERATING SEGMENTS
TABLE 40 VECTURA: COMPANY SNAPSHOT
TABLE 41 VECTURA: OPERATING SEGMENTS
TABLE 42 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 43 PFIZER: OPERATING SEGMENTS
TABLE 44 ABBOTT: COMPANY SNAPSHOT
TABLE 45 ABBOTT: OPERATING SEGMENTS

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Asthma and COPD Drugs Market- Global Opportunity Analysis and Industry Forecasts, 2014-2022

  • Online Only
  • $4176
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo